A pivotal moment for BioCryst Pharmaceuticals (BCRX) is approaching.

In the next few months, the Durham, N.C.-based biotech will announce results from a Phase 3 clinical trial of its lead drug targeting a rare, genetic disease called hereditary angioedema. The outcome of the study is super important for BioCryst. Positive results mean a likely marketing approval and hundreds of millions of dollars in sales. If the study fails, BioCryst’s drug-development efforts start from scratch.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy